Bayer’s Perfect Alignment: Legal Clarity and Structural Overhaul Drive Shares to New Highs

Bayer shares hit 52-week high after Supreme Court ruling cuts legal exposure, new US glyphosate subsidiary Ruveon, and Deutsche Bank upgrade to Buy with €60 target.

Bayer shares roared to life on Thursday, vaulting 9.40% to hit €53.28 – a level that marks both a fresh 52-week peak and the stock’s highest point of the year. The explosive move was powered by a rare confluence of events: a landmark Supreme Court ruling that slashed the company’s legal exposure and a strategic restructuring of its troubled US glyphosate business. For investors who have weathered years of litigation uncertainty, the message could not be clearer – the narrative around the German pharmaceutical and agricultural giant is undergoing a fundamental shift.

At the heart of the operational overhaul lies Ruveon LLC, a newly created subsidiary headquartered in St. Louis that will assume control of Bayer’s entire US glyphosate portfolio. Alfonso Alba Ordóñez has been appointed chief executive of the standalone unit, which remains wholly owned by Bayer but is designed to operate with greater agility in the American market. Market observers view the move as more than a simple internal reorganisation; it is widely interpreted as a preparatory step for a potential partial sale or full spin-off that would cordon off the legacy litigation risks from the rest of the group. The carve-out is part of a five-year roadmap for the Crop Science division that was unveiled last year.

The legal tailwind has been equally decisive. On June 25, the US Supreme Court sided with Bayer in the Durnell case, ruling that federally mandated labelling requirements preempt state-level claims over inadequate cancer warnings. The decision effectively gutted thousands of pending lawsuits, removing what had been the most threatening source of liability. With the judicial overhang dissipating, Bayer’s existing provisions now appear sufficient to cover the remaining cases, paving the way for a final settlement. A court-approved $7.25 billion class-action agreement is scheduled for a conclusive hearing on August 19, 2026 – a date that could mark the ultimate end of the Roundup saga.

The improving backdrop prompted a swift reaction from Deutsche Bank. Analyst Virginie Boucher-Ferte upgraded the stock from “Hold” to “Buy” and raised the price target sharply from €45 to €60. Her reasoning mirrors the broader sentiment: as legal distractions fade, investors can again focus on the underlying business, which on most valuation metrics remains cheap relative to peers. The rerating has been dramatic – the shares have added 40.12% since the start of the year and nearly doubled over the past twelve months.

Yet the rally is not solely a story of legal relief and structural separation. Bayer’s pharmaceuticals arm is delivering fresh momentum of its own. Nubeqa, a treatment for prostate cancer, posted first-quarter sales growth of 57%, while Kerendia, used for chronic kidney disease, surged 84%. The pipeline has also received a high-tech boost: a new partnership with Iambic Therapeutics will deploy an artificial intelligence platform to speed up the discovery of novel drug candidates in oncology and cardiology.

Such rapid appreciation, however, has left the stock looking stretched from a technical perspective. The Relative Strength Index has climbed to 85.3, deep into overbought territory and well above the 70 threshold that typically signals a near-term pullback risk. The stock now trades 44.03% above its 200-day moving average of €36.99, while annualised 30-day volatility stands at 63.86%. For momentum traders, the chart is flashing caution signs even as the fundamental story brightens.

Looking ahead, the next catalysts are tightly clustered. Bayer is due to report second-quarter results on August 4, offering a first look at the financial impact of the Ruveon restructuring and the pharma division’s trajectory. Then, on August 19, the US court will decide whether to give final approval to the $7.25 billion settlement. A green light would clear the decks of the company’s biggest overhang – and could prompt the next leg of the re-rating that has already reshaped the investment case for one of Europe’s most closely watched turnaround plays.